Member Info for The_Paladin

Fruitsnveg. Like you, I view the exchanges on the advfn Synairgen board as being somewhat deranged. I do not follow that board. Certainly not any of the individuals that contribute to it. I lack the ability to discern anything whatsoever from their very odd dialogue. It is as though they are communicating in a code known only to themselves.

I did have a brief peek at several forums yesterday to see if anyone had an explanation for the higher than usual number of Synairgen shares being traded? On the advfn board, amidst the indiscernible code, I discovered that one individual had copied one of my comments from this forum verbatim onto the advfn board? I found this odd to say the least. I believe that it was a futile attempt at goading me from afar? I subsequently used it as an example of the type of pointless immature behaviour that we should try to avoid on this forum.

To answer your other point, sadly I have no particular skill that might influence trading to benefit the Synairgen share price. If only that were the case. Like all investors, I continue to wait, impatiently at times, as some of my recent comments demonstrate, for information from the company which might have a positive impact on the share price. It appears that I may have a long wait ahead? However, as stated earlier, I now believe that if and when concrete evidence emerges, some interest from a large pharmaceutical entity may well come to the fore? IMHO only. DYOR etc.

Professional.

The investors in this board are not being played by the company, or anyone else. That may have been true 19 months+ ago, when I was carried along by the hype that came from so-called “knowledgable” investors on various forums. We all thought at the time that our Synairgen investments were once in a lifetime golden tickets to a substantial profit. The company didn’t encourage any of us to invest, nor to remain invested. It was all down to individual decisions, nothing more.

As to the present, investors are remaining invested as we believe that, based on the information at our disposal, there is a fair chance that the company’s strategy will result in decent P2 results. Additionally that our investment will recover from its current depleted state.

Please cease from goading others. You have argued well previously. A return to sensible comments would be appreciated.

There is another forum - the advfn board, which specialises in unintelligible dialogue. One pointless commentator on that board quoted one of my more underwhelming comments earlier today. His/her aim is merely to troll, and goad others. Certainly not to indulge in a sensible conversation about the company and its future.

Please refrain from reducing the conversation to that individual’s level. Your cooperation with this would be appreciated.

Thanks jonnyboy33. We are on the same page with this investment, as are many others on this forum. It has indeed been a very long wait for some positive news. I remain confident that SNG001’s journey towards commercialisation will continue. From past experience with this company, I am seriously thinking that the baton will need to be handed on at some stage to complete the race.

ATB to you and all other LTIs. In addition, wishing Doc.D a swift recovery to good health!

Thank you for your reply Doc83. You are right, of course. I trust that your most pessimistic forecast doesn’t come to pass, as was the case in Feb 2022! Let us all hope for better times ahead, and that the company’s current strategy comes to fruition at some, as yet indeterminate, time in the future.

On reflection, I now wish that I hadn’t posted yesterday. I was expressing my frustration at the glacially slow progress during the last 19 months, and the lack of communication with investors and the wider market.

Another company, in which I am invested, provides investors with significant quarterly updates, by way of a newsletter. The company is gaining some traction recently, and the significant markets that have been laid down over the last few years are now helping to attract new investment. Their initiatives are now gaining serious attention.

A similar effort from Synairgen would undoubtedly be helpful. However, from past experience, I realise that this is highly unlikely to happen!

Earlier, I was offered 6.9p when I set up a dummy sell of 100K shares.

I find this surprising! It seems that the strategy the company has in place is not being communicated effectively to the market?

Someone recently rightly commented on the CEO’s lethargy in the recent short Proactive Investors interview. Dr Monk presents highly technical information monotonically. To put it candidly, he is boring. Likewise, the recent written communications are for the scientifically literate. They probably wouldn’t command the attention of an investor, who is seeking an innovative and potentially significant product? There is a lot of competition for investment in Synairgen’s space, and we are failing to grab any attention?

What became of the advertised science writer position? The company is in need of literature, which will capture the attention of investors, as well as punchy presenters, who are able to deliver the appropriate information with panache and conviction.

Our future depends on the success of the forthcoming P2 trials, and what they might lead to. Meanwhile, it would be useful if our underworking executives put their heads together, and come up with some ideas to convince the market that Synairgen is alive and well, and a potential bargain for future investors.

Thank you Fruitsnveg.

Prior to your comment, I too had misunderstood that Synairgen were about to arrange their own investigator-led, and observational trials in order to determine the optimum patient groups for the anticipated P2 mini trials? It seems then what they were referring to this in the recent interim statement, they meant that they will used data from the Southampton CTU’s UNIVERSAL trial? This was my understanding previously, but was subsequently confused by the company’s statement.

There have been a few misleading comments from various sources this week. Wigster77 pointed out the statement concerning an anticipated P3 trial in H1 2024? I fully agree with him that it will take longer for this to happen. We are nearly into October 2023, and the process leading to determining the patient groups for the two P2 trials is nowhere near complete.

The Synairgen board stated at the end of the AGM that they intended to communicate more frequently to keep investors up to date with developments as they occur. It would be useful if their statements were clear and unequivocal. This would avoid avoid confusion such as those concerning the pre-trial studies, and likely future timelines.

My understanding is that the company is slowly moving towards a P3 trial, and possible future commercialisation, of SNG001. The Board and CEO really do need to improve their communication with investors, and with the market. IMHO it is their failure with this aspect of their business that has led to the share price collapsing to our current abysmally low level.

Likewise, I bought my portfolio of IQ-AI stock over the last three years, and have held all my stock through thick and thin. I foresaw the potential of this company, and the integrity of the IB team persistently shone through like a guiding light.

Previously, my target sell price was 15-20p. I have seen enough recently to stick around beyond that range should it be attained, and to see what happens?

More patience is required. However, the current potential of this stock is well ahead of that of my other investments.

Saliva. Your abrupt return to this forum yesterday is noted. The fact that you are shorting this stock is blatantly obvious. Your attempt at scaremongering is transparent. No need for you to reply. Your unhelpful comments are now filtered.

Today’s RNS was the expected six monthly update on the company’s current progress, and on its financial situation. There was nothing too unexpected in the company’s summary or in the associated reporting. Coincidentally or otherwise, Dr. Monk’s recent article was the featured editorial in today’s edition of Pharmaceutical Online.

Oddly although all is more or less as expected, the share price has dropped by 17.53%, on the back of 200000 shares being traded. Most of these trades are reported as buys, with the bid having dropped to 7.01p. An overreaction to an unremarkable day of reporting and an underwhelming day’s trading, or am I failing to understand something about the process?

https://www.pharmaceuticalonline.com/doc/respiratory-viral-infections-the-next-frontier-for-antiviral-drug-development-0003?vm_alias=Archive%20Link&utm_source=mkt_PHARM&utm_medium=email&utm_campaign=PHARM_09-21-2023&utm_term=1265e580-0128-4ee8-99fb-877c28aa031a&utm_content=Archive%20Link&mkt_tok=MDc1LU5WQy0wODYAAAGOV0np1fBitWw4zvWA8CzAW2Q8qnF3Lx-lJXFp99rDYUOtCsaaGOPhGXmBD-DnD4sqza8b9NOC1jYXUntRgOE8T4G1UI_Hom2_2g5YGFwXt39dAKg

Thanks Doc83.

This note puts a positive spin on our current state of play. It reiterates all the golden eggs in Synairgen's basket, which investors are well acquainted with by now. In addition, it highlights the company's aspiration for SNG001, should it eventually demonstrate successful mini-PII and PIII results. As investors, we must retain our belief in the potential of SNG001, although all must be disappointed with the current rate of progress.

I noted the following at the foot of today's statement:

"The Company also announces that its Nominated Adviser and Joint Broker has changed its name to Cavendish Capital Markets Limited following completion of its own corporate merger."

Their statement, on behalf of a company that they represent, naturally aspires towards an optimistic forecast.

Synairgen has been in a state of suspension for 19 months. Nothing new has happened, and the company's share price has contracted to pre - CV19 levels. It is an aspiring University spinoff entity once again.

The cash reserve is solely from investor capital for the last Phase III trial. The company has not taken appropriate measures to reduce running costs. It has retained executives, who are unable to fulfil the roles for which they are appointed. Additionally, the salaries and benefit packages of the three most senior executives are too high for a company in a state of transition, with no discernible progress made this year.

Re-presenting the company's data at conferences is an unnecessary expense. The focus should be on getting Synairgen back on track. Should they continue to fail to show progress, as as present, they will run out of cash, and all investors will lose their capital. My only positive following today's announcement of further trial delay is that TFG Asset Management continue to hold. Perhaps the expertise at their disposal can discern more from the current situation than I am able to make of it, as things stand?

Alessandro Zamboni's lack of delivery has been a major disappointment. When the share price touched on 0.14p earlier this year, I contemplated selling my stock, albeit at a loss. On reflection, I subsequently perceived a period of consolidation, followed by a further rise, in line with the company's strategy. At first, I thought I had made the right call when the share price stabilised.

The recent change in sentiment has proved me to be totally wrong. I shall continue to hold my investment, as I believe that it will eventually deliver a good return. However, I intend to sell if and when I am reasonably in profit ( > 0.18p).

One puzzling question is why Mr. Zamboni is involved with RTOP? Surely his time and attention would have been better served towards bringing SYME to fruition?

That is a fair comment Professional. I have no idea of the context of the relationship between Synairgen and the pharmaceutical company. I gather that the information emerged from a conversation between a contributor to this forum and Simon Shaw, Synairgen’s Chairperson at the recent AGM. Mr. Shaw is unlikely to have volunteered that information if it hadn’t emerged from a serious discussion concerning a future partnership?

We were close to success at the last P3 trial. I believe that a change to a factor or factors in the conduct of the trial for example an earlier time span, or an increase in the patient number, might have resulted in a more favourable outcome for the company?

As things stand, I am more optimistic about future possibilities than was the case four months or so ago. You are correct in that the company are keeping trial details closely guarded until they have definitive information for investors. Having waited for some nineteen months, I am prepared to give this investment until the end of next Winter to see how the latest strategy develops? Following last year’s unfortunate failure, I am accepting that this is a binary investment, and remain hopeful of a recovery,

During the excellent feedback from the last AGM, it was mentioned that BP might be interested in our therapy, but that further supporting data would first be needed? I presume that the potential partners could well be GSK or Jansen - through the mutual link with Southampton’s CTU UNIVERSAL trial?

This is all tenuous for the time being, but what if further promising data were to emerge from Synairgen’s multiple P2 trials? Surely GSK and Jansen wouldn’t wait for a bidding war with other large entities? Either or both would want to secure an agreement as early and as cheaply as possible? Perhaps a recovery opportunity might yet be possible for Synairgen by early to mid 2024?

Synairgen have used data stratification to add several degrees of sophistication to their trial design in order to optimise the patient cohort for their trials.

Perhaps I am being too simplistic about this but didn’t the CEO’s comment years ago about SNG001 needing a fire to put out offer a useful start towards optimising patient selection? The failure in previous trials was due to there being no discernible difference between the outcomes between SNG001 and placebo treatment? By selecting patients with severe infections, surely this would offer SNG001 a better opportunity to demonstrate its efficacy?

Both Dr. Monk’s Synairgen - based presentation, and Southampton’s Clinical Trials Unit’s UNIVERSAL presentation, were given at around the same time. You are right in stating that the poster presentation of the UNIVERSAL trial outcomes would have been attended by Southampton CTU employees.

Out of SYME and into RTOP at its launch.

Out of RTOP and back into SYME today for a X3 increase in the investor’s original SYME shareholding.

Anyone who managed to do something similar to this is a very astute investor!

Thanks everyone for the updates regarding the recent presentations. IMHO all bodes well for the future, although our patience will need to endure for the present.

I will look at all this in detail when time avails. Has anyone taken on board whether Dr Monk added anything new to his poster presentation? Alternatively, did he present the summative Sprinter outcomes, perhaps leading to Synairgen’s multiple P2 mini trials ? Momentum is slowly building. Perhaps our patience will be rewarded at some point?

Meanwhile, will our next RNS announce the launch of the mini trials? Start of December at the earliest in my estimation?

IQAI have recently posted this on LinkedIn:

“ The quantitative DSC perfusion processing in FDA-cleared IB Neuro has been validated using a single dose of GBCA for 1.5T (already validated on 3T). The 50% reduction from the common double-dose approach (no preload) does not compromise image quality.”

News of applications of IB technology is proliferating. It is now a matter of time before a share price breakout. A buyout at > £100m is currently possible IMHO?

A recent IB message:

“A huge shout out to the @eaonc ACRIN/ECOG EAF151 team for completing trial accrual! EAF151 is the FIRST trial of its kind – with a goal to evaluate an advanced MRI biomarker for brain tumors. DSC perfusion imaging (@IQAI_IB's IB Neuro) was their choice.”